Adaptive Biotechnologies (ADPT) News Today $10.32 -0.09 (-0.86%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.32 +0.00 (+0.05%) As of 06/13/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADPT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 52-Week High - Time to Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 52-Week High - Here's What HappenedJune 12 at 4:43 AM | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Bought by California State Teachers Retirement SystemCalifornia State Teachers Retirement System boosted its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 1,060.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 97,388 shares of the company's stock after purchasing an adJune 12 at 3:39 AM | marketbeat.com118,593 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 118,593 shares of the company's sJune 11, 2025 | marketbeat.comIs Cathie Wood Cashing Out? Ark CEO Dumps Millions in Biopharma and Aviation StocksJune 10, 2025 | msn.comSquarepoint Ops LLC Raises Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Squarepoint Ops LLC raised its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 265.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,401 shares of the company's stock after acquiringJune 8, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Sets New 12-Month High - Should You Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High - Still a Buy?June 6, 2025 | marketbeat.comTwo Sigma Advisers LP Has $309,000 Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Two Sigma Advisers LP raised its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 396.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,600 shares of the company's stock after acquirinJune 6, 2025 | marketbeat.comTwo Sigma Investments LP Has $1.10 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Two Sigma Investments LP increased its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 251.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 183,838 shares of the compJune 6, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Bank of America Corp DEBank of America Corp DE trimmed its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 69.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 240,996 shares of the company's stock after selling 538,135 sharesJune 6, 2025 | marketbeat.comAlpha Wealth Funds LLC Makes New $297,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Alpha Wealth Funds LLC bought a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 40,000 shares of the company's stock, valued at approximately $297,000.June 4, 2025 | marketbeat.comVoloridge Investment Management LLC Acquires New Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Voloridge Investment Management LLC acquired a new stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 29,093 shares of the company's stock, valuedJune 1, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have givenMay 31, 2025 | marketbeat.comAdaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid CancersMay 30, 2025 | globenewswire.comAdaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceMay 28, 2025 | globenewswire.comAmeriprise Financial Inc. Has $4.42 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Ameriprise Financial Inc. boosted its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 794.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 736,720 shares of the company's stock after buyingMay 27, 2025 | marketbeat.comMan Group plc Increases Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Man Group plc lifted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 80.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 288,689 shares of the company's stock after purchasing an additional 128,317 shares during the periMay 26, 2025 | marketbeat.com29,807 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Bought by Lazard Asset Management LLCLazard Asset Management LLC bought a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 29,807 shares of the company's stock, valued at appMay 26, 2025 | marketbeat.comJanus Henderson Group PLC Buys Shares of 46,900 Adaptive Biotechnologies Co. (NASDAQ:ADPT)Janus Henderson Group PLC bought a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 46,900 shares of the company's stock, valuedMay 26, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Bought by Point72 Asset Management L.P.Point72 Asset Management L.P. increased its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 89.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 937,331 shares ofMay 22, 2025 | marketbeat.comDeutsche Bank AG Grows Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Deutsche Bank AG boosted its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 397.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 630,577 shares of the company's stock after buying an additional 503,842 shares during theMay 22, 2025 | marketbeat.comNorthern Trust Corp Acquires 130,449 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Northern Trust Corp increased its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 13.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,093,981 shares of the company's stock after acquirinMay 22, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Acquired by Soleus Capital Management L.P.Soleus Capital Management L.P. increased its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 168.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,983,142 shares of the company's stock after purchasing an aMay 21, 2025 | marketbeat.com40,914 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by Graham Capital Management L.P.Graham Capital Management L.P. purchased a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 40,914 shares of the company's stock, vMay 21, 2025 | marketbeat.comInsider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CFO Sells 1,929 Shares of StockMay 20, 2025 | insidertrades.comMillennium Management LLC Has $37.72 Million Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Millennium Management LLC cut its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 33.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,292,634 shares of the company's stock after selling 3,10May 20, 2025 | marketbeat.com53,170 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Bought by Balyasny Asset Management L.P.Balyasny Asset Management L.P. purchased a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 53,170 shares of the company's stock, vMay 20, 2025 | marketbeat.comJane Street Group LLC Sells 97,690 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Jane Street Group LLC lessened its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 19.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 406,587 shares of the company's stock after sellMay 18, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 29.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 213,829 shMay 16, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Lowered by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD reduced its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 41.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 93,892 sharesMay 16, 2025 | marketbeat.comDriehaus Capital Management LLC Buys 410,877 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Driehaus Capital Management LLC grew its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 94.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 846,171 shares of the company's stock after purMay 12, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by Dimensional Fund Advisors LPDimensional Fund Advisors LP raised its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 12.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,604,876 shares of the company's stock after buying an additionaMay 12, 2025 | marketbeat.comAlgert Global LLC Boosts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Algert Global LLC raised its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 464.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 430,514 shares of the company's stoMay 10, 2025 | marketbeat.comCaxton Associates LP Buys New Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Caxton Associates LP purchased a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 123,287 shares of the company's stocMay 9, 2025 | marketbeat.comAdaptive Biotechnologies Reaches Analyst Target PriceMay 7, 2025 | nasdaq.comAdaptive Biotechnologies Reaches Analyst Target PriceMay 7, 2025 | nasdaq.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Insider Harlan S. Robins Sells 68,412 SharesAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) insider Harlan S. Robins sold 68,412 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $7.35, for a total value of $502,828.20. Following the sale, the insider now owns 1,279,524 shares in the company, valued at $9,404,501.40. The trade was a 5.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.May 7, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Given Consensus Rating of "Moderate Buy" by AnalystsAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating toMay 7, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading Volume on Analyst UpgradeAdaptive Biotechnologies (NASDAQ:ADPT) Sees Large Volume Increase Following Analyst UpgradeMay 7, 2025 | marketbeat.comMorgan Stanley Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock PriceMorgan Stanley increased their price objective on Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Monday.May 7, 2025 | marketbeat.com37,759 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by Susquehanna Fundamental Investments LLCSusquehanna Fundamental Investments LLC bought a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 37,759 shares of the company's stock, valueMay 7, 2025 | marketbeat.com5 Analysts Assess Adaptive Biotechnologies: What You Need To KnowMay 5, 2025 | benzinga.comAdaptive Biotechnologies (NASDAQ:ADPT) Issues Earnings ResultsAdaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.08. The business had revenue of $52.44 million during the quarter, compared to the consensus estimate of $42.13 million. Adaptive Biotechnologies had a negative return on equity of 64.65% and a negative net margin of 89.12%. The company's quarterly revenue was up 25.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.33) earnings per share.May 5, 2025 | marketbeat.comAristotle Atlantic Partners LLC Sells 114,499 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Aristotle Atlantic Partners LLC reduced its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 3.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,886,702 shares of the company's stMay 5, 2025 | marketbeat.comTudor Investment Corp ET AL Sells 57,284 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Tudor Investment Corp ET AL trimmed its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 11.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 458,488 shares of the company's stoMay 5, 2025 | marketbeat.comBarclays PLC Grows Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Barclays PLC lifted its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 15.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 266,066 shares of the company's stock after acquiring an additional 35,889 shares during thMay 5, 2025 | marketbeat.comAdaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57May 4, 2025 | finance.yahoo.comAdaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month High Following Better-Than-Expected EarningsAdaptive Biotechnologies (NASDAQ:ADPT) Reaches New 12-Month High Following Earnings BeatMay 4, 2025 | marketbeat.comAdaptive Biotechnologies First Quarter 2025 Earnings: Beats ExpectationsMay 3, 2025 | uk.finance.yahoo.comAdaptive Biotechnologies stock soars on Q1 earnings beatMay 2, 2025 | investing.comPDT Partners LLC Increases Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT)PDT Partners LLC boosted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 12.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 316,281 shares of the company's stock after acquiring an additional 35,899 shares during the perMay 2, 2025 | marketbeat.com Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address ADPT Media Mentions By Week ADPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADPT News Sentiment▼1.070.89▲Average Medical News Sentiment ADPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADPT Articles This Week▼65▲ADPT Articles Average Week Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TG Therapeutics News Today Grifols News Today Lantheus News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Nuvalent News Today Axsome Therapeutics News Today ADMA Biologics News Today Vaxcyte News Today Akero Therapeutics News Today Rhythm Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADPT) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
